{"id":"pegylated-filgrastim","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"10-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":null,"effect":"Splenomegaly"}]},"_chembl":{"chemblId":"CHEMBL1201567","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Filgrastim is a recombinant human G-CSF that binds to G-CSF receptors on hematopoietic progenitor cells, promoting their proliferation, differentiation, and activation. Pegylation extends the drug's half-life by reducing renal clearance, allowing for less frequent dosing compared to standard filgrastim while maintaining sustained neutrophil production during chemotherapy-induced neutropenia.","oneSentence":"Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:48.682Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced neutropenia in patients with non-myeloid malignancies"},{"name":"Reduction of infection risk in cancer patients receiving myelosuppressive chemotherapy"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT07020533","phase":"PHASE1","title":"A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-05-08","conditions":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":46},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT07434063","phase":"","title":"Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection","status":"RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-06-18","conditions":"Neutropenia","enrollment":200},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT05799612","phase":"PHASE1","title":"Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-22","conditions":"Angiosarcoma","enrollment":""},{"nctId":"NCT07101445","phase":"PHASE4","title":"Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-09-24","conditions":"Multiple Myeloma","enrollment":94},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT07046078","phase":"PHASE2","title":"Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-26","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia","enrollment":20},{"nctId":"NCT07367178","phase":"PHASE2","title":"Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"MedSIR","startDate":"2026-07","conditions":"Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Triple-Negative Breast Cancer","enrollment":30},{"nctId":"NCT04370301","phase":"PHASE2","title":"Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-02-09","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":20},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT07205536","phase":"PHASE2","title":"Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy","status":"RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2025-08-01","conditions":"Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy","enrollment":30},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT04871607","phase":"PHASE2","title":"Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-02","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":33},{"nctId":"NCT05076682","phase":"PHASE2","title":"Reverse Triple Negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-30","conditions":"Triple-negative Breast Cancer","enrollment":80},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":510},{"nctId":"NCT06212752","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-06-13","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":39},{"nctId":"NCT03670966","phase":"PHASE1, PHASE2","title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-07-10","conditions":"Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission","enrollment":30},{"nctId":"NCT04797767","phase":"PHASE1, PHASE2","title":"Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-02-04","conditions":"Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia","enrollment":62},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT05722015","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-14","conditions":"Metastatic Non-small Cell Lung Cancer","enrollment":377},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06254742","phase":"PHASE3","title":"A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies","status":"WITHDRAWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-02","conditions":"Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk","enrollment":""},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT04195945","phase":"PHASE2","title":"CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-03-11","conditions":"Acute Myeloid Leukemia, Myeloid Neoplasm","enrollment":60},{"nctId":"NCT02582697","phase":"PHASE3","title":"Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2014-02","conditions":"Germ Cell Tumor","enrollment":500},{"nctId":"NCT05463601","phase":"PHASE2","title":"Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08-01","conditions":"Metastatic Breast Cancer","enrollment":132},{"nctId":"NCT05294055","phase":"PHASE2","title":"Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-04-26","conditions":"Multiple Myeloma, Lymphoma","enrollment":120},{"nctId":"NCT06958614","phase":"","title":"Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2019-09-02","conditions":"Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status","enrollment":213},{"nctId":"NCT06926751","phase":"PHASE2","title":"Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-07","conditions":"Solid Tumors, Children, Adolescent","enrollment":132},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT04023669","phase":"PHASE1","title":"Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-08","conditions":"Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory","enrollment":21},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06684158","phase":"PHASE2","title":"Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2024-11-30","conditions":"GC/GEJC","enrollment":70},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT01783535","phase":"PHASE2","title":"Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-06-19","conditions":"Retinoblastoma","enrollment":174},{"nctId":"NCT05536154","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-11-01","conditions":"Lymphoma, Multiple Myeloma","enrollment":68},{"nctId":"NCT05970185","phase":"EARLY_PHASE1","title":"The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2024-02-01","conditions":"Granulocyte Colony-Stimulating Factor","enrollment":40},{"nctId":"NCT03858166","phase":"PHASE4","title":"Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer","status":"TERMINATED","sponsor":"Shandong University","startDate":"2017-12-01","conditions":"Adjuvant Chemotherapy, Ovarian Neoplasms, Ovarian Cancer","enrollment":68},{"nctId":"NCT06188676","phase":"PHASE3","title":"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL","status":"RECRUITING","sponsor":"National Research Center for Hematology, Russia","startDate":"2022-04-01","conditions":"Primary Mediastinal Lymphoma","enrollment":100},{"nctId":"NCT04196010","phase":"PHASE1","title":"Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-05-08","conditions":"Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT02649673","phase":"PHASE1","title":"LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-03-23","conditions":"Small Cell Lung Cancer, Ovarian Cancer","enrollment":34},{"nctId":"NCT03961919","phase":"PHASE2","title":"Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant","status":"COMPLETED","sponsor":"Ciceri Fabio","startDate":"2009-02-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes, Transplant-Related Hematologic Malignancy","enrollment":15},{"nctId":"NCT05510089","phase":"NA","title":"Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies","status":"UNKNOWN","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2022-09-01","conditions":"Hematological Malignancy","enrollment":62},{"nctId":"NCT01177683","phase":"PHASE1, PHASE2","title":"Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma","status":"TERMINATED","sponsor":"Sherif Farag, MB, BS","startDate":"2010-07","conditions":"Multiple Myeloma","enrollment":32},{"nctId":"NCT06060080","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma","status":"UNKNOWN","sponsor":"Yao Liu","startDate":"2022-04-22","conditions":"Lymphoma, Multiple Myeloma","enrollment":7},{"nctId":"NCT06026995","phase":"PHASE4","title":"Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells","status":"UNKNOWN","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-03-01","conditions":"Lymphoma","enrollment":174},{"nctId":"NCT04542356","phase":"PHASE2","title":"Study on the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia During Concurrent Chemoradiotherapy of Cervical Cancer","status":"COMPLETED","sponsor":"Chongqing University Cancer Hospital","startDate":"2018-08-01","conditions":"Cervical Cancer","enrollment":60},{"nctId":"NCT03531918","phase":"PHASE1, PHASE2","title":"Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine & Mitoxantrone for Untreated AML & High-Grade Myeloid Neoplasm","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-09-14","conditions":"Acute Myeloid Leukemia","enrollment":66},{"nctId":"NCT00003388","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-07-26","conditions":"Lymphoma","enrollment":38},{"nctId":"NCT05834751","phase":"NA","title":"the Efficacy and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells in Lymphoma","status":"UNKNOWN","sponsor":"Ou Bai, MD/PHD","startDate":"2023-05-01","conditions":"Lymphoma","enrollment":144},{"nctId":"NCT04477616","phase":"PHASE2","title":"Injection Regimen Trial of PEG-rhG-CSF During Breast Cancer Chemotherapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-07-13","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT04554056","phase":"PHASE2, PHASE3","title":"Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2020-09-21","conditions":"Breast Cancer Female","enrollment":586},{"nctId":"NCT05531279","phase":"NA","title":"A Study of PEG-rhG-CSF and rhG-CSF Used for Aplastic Anemia Granulocyte Deficiency","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-06-05","conditions":"Severe Aplastic Anemia","enrollment":45},{"nctId":"NCT00198991","phase":"PHASE4","title":"German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)","status":"COMPLETED","sponsor":"Goethe University","startDate":"2003-04","conditions":"Adult Acute Lymphocytic Leukemia","enrollment":1883},{"nctId":"NCT04460508","phase":"PHASE2","title":"Mecapegfilgrastim(PEG-G-CSF) for Prophylaxis of Chemotherapy-induced Neutropenia in Patients With Lymphoma","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2020-12-20","conditions":"Chemotherapy-induced Neutropenia, Lymphoma","enrollment":170},{"nctId":"NCT05409547","phase":"PHASE4","title":"A Clinical Study of Autologous Peripheral Blood Stem Cell Mobilization for PEG-G-CSF","status":"UNKNOWN","sponsor":"Ning Huang","startDate":"2022-06-30","conditions":"Granulocyte Colony-stimulating Factor, Stem Cell Mobilization","enrollment":80},{"nctId":"NCT04466137","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Safety and Efficacy of YPEG-rhG-CSF in Malignancies Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2020-10-16","conditions":"Non-Myeloid Malignancy","enrollment":398},{"nctId":"NCT05222009","phase":"PHASE1","title":"G-CSF in Patients With Anti-PD-1-axis Therapy-resistant Recurrent or Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-01-24","conditions":"Granulocyte Colony-Stimulating Factor, PD-1 Inhibitor","enrollment":25},{"nctId":"NCT05156554","phase":"NA","title":"PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-12","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT04547829","phase":"PHASE2","title":"Safety and Efficacy of PEG-rhG-CSF in Preventing Neutropenia in Children With Tumor After Chemotherapy","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-10-10","conditions":"Pediatric Cancer","enrollment":108},{"nctId":"NCT04773327","phase":"NA","title":"Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological Malignancies","status":"UNKNOWN","sponsor":"Xiaohua Wu MD","startDate":"2021-05","conditions":"Gynecologic Malignant Tumor","enrollment":150},{"nctId":"NCT01753453","phase":"PHASE2","title":"An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-06","conditions":"Multiple Myeloma","enrollment":23},{"nctId":"NCT02392793","phase":"PHASE1","title":"Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2015-03-25","conditions":"Childhood Solid Tumors","enrollment":43},{"nctId":"NCT01169636","phase":"PHASE1, PHASE2","title":"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-31","conditions":"Hodgkin's Lymphoma","enrollment":62},{"nctId":"NCT00671658","phase":"PHASE2","title":"Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2002-11","conditions":"Leukemia, Acute Lymphoblastic Leukemia","enrollment":220},{"nctId":"NCT04009941","phase":"PHASE4","title":"Efficacy and Safety of 4.5mg PEG-rhG-CSF Per Cycle in Preventing Neutropenia After Intensive Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Peking University","startDate":"2019-08-01","conditions":"Breast Cancer, Neutropenia","enrollment":104},{"nctId":"NCT00101010","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-09","conditions":"Lymphoma","enrollment":80},{"nctId":"NCT00290433","phase":"PHASE2","title":"Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-09","conditions":"Lymphoma","enrollment":55},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04500886","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Hemophagocytic Syndrome","enrollment":50},{"nctId":"NCT04497688","phase":"NA","title":"Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-01-01","conditions":"Non Hodgkin's Lymphoma","enrollment":104},{"nctId":"NCT04497701","phase":"NA","title":"Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-08-01","conditions":"Lymphoma, Leukemia","enrollment":139},{"nctId":"NCT02390843","phase":"PHASE1","title":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-02","conditions":"Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT02215200","phase":"PHASE2","title":"ATG-GCSF in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2014-12","conditions":"Diabetes Mellitus, Type 1","enrollment":89},{"nctId":"NCT04239001","phase":"NA","title":"Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2020-02","conditions":"Advanced Pancreatic Cancer","enrollment":20},{"nctId":"NCT04171986","phase":"NA","title":"Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-11-10","conditions":"Small Cell Lung Cancer","enrollment":93},{"nctId":"NCT04083079","phase":"PHASE4","title":"Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-08-01","conditions":"Lymphoma, Non-Hodgkin, Granulocyte Colony-Stimulating Factor, Cost-Benefit Analysis","enrollment":250},{"nctId":"NCT00254410","phase":"PHASE2","title":"FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-03-14","conditions":"Chronic Lymphocytic Leukemia","enrollment":30},{"nctId":"NCT02392039","phase":"EARLY_PHASE1","title":"Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-12-14","conditions":"Lymphoma","enrollment":1},{"nctId":"NCT03870412","phase":"NA","title":"Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-22","conditions":"Elderly Lymphoma Patients","enrollment":485},{"nctId":"NCT02533362","phase":"PHASE1, PHASE2","title":"ANF-Rho in the Treatment of Chronic Neutropenia","status":"WITHDRAWN","sponsor":"Prolong Pharmaceuticals","startDate":"2015-10","conditions":"Neutropenia, Severe Chronic","enrollment":""},{"nctId":"NCT03846414","phase":"","title":"Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2019-02-13","conditions":"Chemotherapy-induced Neutropenia, Myelosuppression","enrollment":1500},{"nctId":"NCT03559387","phase":"PHASE2","title":"Randomized Phase 2, Dose-finding Efficacy, Safety Study of ANF-RHO™ Versus Neulasta® in Chemotherapy-Induced Neutropenia","status":"TERMINATED","sponsor":"Prolong Pharmaceuticals","startDate":"2017-08-03","conditions":"Chemotherapy-induced Neutropenia","enrollment":9},{"nctId":"NCT02944604","phase":"PHASE4","title":"The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy","status":"COMPLETED","sponsor":"Peking University","startDate":"2016-09-08","conditions":"Breastcancer","enrollment":240},{"nctId":"NCT02963389","phase":"PHASE1","title":"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2016-10-04","conditions":"Solid Tumor, Lymphoma","enrollment":27},{"nctId":"NCT03776604","phase":"NA","title":"PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy","status":"UNKNOWN","sponsor":"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.","startDate":"2018-12-05","conditions":"Small Cell Lung Cancer, PEG-rhG-CSF","enrollment":61},{"nctId":"NCT03731442","phase":"PHASE3","title":"Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences","startDate":"2018-11-01","conditions":"Esophageal Cancer","enrollment":300},{"nctId":"NCT02650193","phase":"PHASE2","title":"A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-12","conditions":"Non-metastatic Breast Cancer","enrollment":25},{"nctId":"NCT03701841","phase":"","title":"Efficacy, Safety and Cost-effectiveness of PEG-rhG-CSF for Primary vs Secondary Prophylaxis","status":"UNKNOWN","sponsor":"Anhui Provincial Hospital","startDate":"2018-10","conditions":"Chemotherapy-induced Neutropenia","enrollment":1000},{"nctId":"NCT01443078","phase":"PHASE2","title":"Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-10","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT02005458","phase":"PHASE2","title":"Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy","status":"COMPLETED","sponsor":"Xiamen Amoytop Biotech Co., Ltd.","startDate":"2013-12","conditions":"Non Small Cell Lung Cancer, Breast Cancer","enrollment":80},{"nctId":"NCT03206229","phase":"PHASE1","title":"Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Adello Biologics, LLC","startDate":"2017-02-13","conditions":"Healthy Volunteers","enrollment":120},{"nctId":"NCT00389818","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-01","conditions":"Lymphoma","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Pegylated filgrastim","genericName":"Pegylated filgrastim","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegylated filgrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) that stimulates the production and release of neutrophils from bone marrow to reduce infection risk in chemotherapy patients. Used for Chemotherapy-induced neutropenia in patients with non-myeloid malignancies, Reduction of infection risk in cancer patients receiving myelosuppressive chemotherapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}